Research & Development

A Child's Location Determines Their Cancer Survival Rate
Research & Development A Child's Location Determines Their Cancer Survival Rate

A comprehensive global study has brought to light the profound and deeply concerning disparities in survival rates among children diagnosed with cancer, revealing a stark divide that correlates directly with a country's socioeconomic development. The research, which aggregates data from numerous

What Are the New Priorities in Oncology Funding?
Research & Development What Are the New Priorities in Oncology Funding?

The landscape of oncology funding is undergoing a profound and strategic transformation, moving decisively away from supporting purely theoretical research toward projects with a clear and direct path to real-world application. Grant-making organizations are now signaling a clear preference for

Takeaway Meals Drive Inflammation and Heart Disease Risk
Research & Development Takeaway Meals Drive Inflammation and Heart Disease Risk

With a rich background in biopharmaceutical research and a keen eye on the intersection of technology and health, Ivan Kairatov has dedicated his career to understanding the molecular underpinnings of chronic disease. His work provides critical insights into how modern lifestyle choices,

Preoperative MRI vs. Standard Workup: A Comparative Analysis
Research & Development Preoperative MRI vs. Standard Workup: A Comparative Analysis

In the precise and high-stakes world of breast cancer treatment, the prevailing assumption that more detailed imaging invariably leads to better patient outcomes is facing a significant and evidence-based challenge. For years, clinicians have debated the role of preoperative magnetic resonance

Targeted Combo Therapies Boost Survival in Aggressive AML
Research & Development Targeted Combo Therapies Boost Survival in Aggressive AML

A transformative shift is underway in the treatment of Acute Myeloid Leukemia, offering renewed hope for patients battling the most aggressive and resistant forms of this devastating blood cancer. For years, the prognosis for individuals with relapsed or refractory AML has been bleak, with standard

Arcus Halts TIGIT Drug Trial in Major Blow to Gilead
Research & Development Arcus Halts TIGIT Drug Trial in Major Blow to Gilead

The landscape of cancer immunotherapy was shaken as Arcus Biosciences announced the termination of a pivotal Phase 3 trial for its TIGIT-targeting drug, domvanalimab. The decision, prompted by a finding of "futility," delivers a significant setback to its partner Gilead Sciences and casts further

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later